MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dopaminergic neurons"

  • 2016 International Congress

    Diverse effects of alpha-synuclein fibrils on various neuron cell lines, using different buffers

    F. Aliakbari, D. Morshedi, A.A. Shabani, H. Mohammad Beigi, A. Tayaranian Marvian, P. Shariati, S.A. Shojaosadati, A.A. Saboury (Semnan, Islamic Republic of Iran)

    Objective: To investigate the neurotoxic properties of alpha-synuclein (α-Syn) aggregation in different buffers including PBS, SBF and Tris on altered cell lines, SHSY5Y, SK-N-MC and…
  • 2016 International Congress

    Deficiency of HGprt in Lesch-Nyhan disease is associated with abnormal dopaminergic neurodevelopment in vivo

    J.E. Visser, J.S. Witteveen, N.H.M. van Bakel, G.J.M. Martens, S.M. Kolk (Nijmegen, Netherlands)

    Objective: To determine the in vivo effects of hypoxanthine-guanine phosphoribosyl transferase (HGprt) deficiency on dopaminergic neurodevelopment in a genetic mouse model of Lesch-Nyhan disease (LND).…
  • 2016 International Congress

    Functional characterisation and the selective vulnerability of SNCA (A30P) patient-derived midbrain dopaminergic neurons to ER stress

    P.A. Barbuti, B.F.R. Santos, S. Delcambre, Y. Nonnenmacher, C.D. Obermaier, A. Hummel, K. Hiller, R. Krueger (Belvaux, Luxembourg)

    Objective: To functional characterise and phenotype the genetic Parkinson's disease (PD) patient with an A30P point mutation in SNCA using midbrain dopaminergic neurons (mDANs) vs…
  • 2016 International Congress

    Multimodal imaging assessment of nigrostriatal pathway in Parkinson’s disease using 11C-PE2I PET and neuromelanin-sensitive MR

    A. Martin-Bastida, N.P. Lao-Kaim, A.A. Roussakis, W. Li, M. Politis, N. Valle-Guzman, Z. Kefalopoulou, G. Paul, H. Widner, T. Foltynie, R. Barker, P. Piccini (London, United Kingdom)

    Objective: To evaluate the nigrostratal pathway with multimodal assessment using striatal 11C-PE2I PET and nigral Neuromelanin-sensitive MR in Parkinson's disease. Background: The main pathological features…
  • 2016 International Congress

    Characterisation of the A30P mutation in alpha-synuclein gene in patient-derived cellular model of Parkinson’s disease

    B.F.R. Santos, P.A. Barbuti, I. Boussaad, A. Hummel, R. Krüger (Belval, Luxembourg)

    Objective: In this study, we aim to generate and characterise patient-derived midbrain dopaminergic neurons (mDANs) of the A30P Parkinson's disease (PD) familial case. Our goal…
  • 2016 International Congress

    Comparison of DAT and DOPA PET tracer for assessing severity and progression in patients with Parkinson’s disease

    W. Li, N.P. Lao-Kaim, A.A. Roussakis, A. Martin-Bastida, C. Loane, N. Valle-Guzman, Z. Kefalopoulou, M. Politis, T. Foltynie, R.A. Barker, P. Piccini (London, United Kingdom)

    Objective: The aims of this study were to quantify striatal uptake of 18F-DOPA and 11C-PE2I in the same group of PD patients, to assess the…
  • 2016 International Congress

    Pre-formed fibrils injection worsen pathology caused by AAV-mediated over expression of α-synuclein

    L.S. Breger, P. Thakur, O.W. Wan, B. Mattsson, K. Luk, V.M. Lee, J. Trojanowski, A. Björklund (Lund, Sweden)

    Objective: The overall goal is to produce a rat model of Parkinson's disease (PD), which reproduces progressive pathological changes, while displaying profound neuronal cell loss…
  • 2016 International Congress

    Impact of white matter hyperintensity on motor compensation in Parkinson’s disease

    J.J. Lee, Y. Lee, S.J. Chung, P.H. Lee, Y.H. Sohn (Seoul, Korea)

    Objective: To investigate the potential impact of white matter hyperintensity (WMH) on motor compensation in Parkinson's disease (PD). Background: WMHs, the loss of vascular integrity,…
  • 2016 International Congress

    Presynaptic dopamine depletion predicts late complications and time of progression to advanced disease in patients with early Parkinson’s disease

    R. Djaldetti, L. Greenbaum, M. Lorberboym (Petah Tiqva, Israel)

    Objective: To investigate whether the degree of reduced dopamine transporter binding in the striatum is a risk factor for late complications and time of progression…
  • 2016 International Congress

    The relationship among clinical features, DAT scintigraphy and MIBG cardiac scintigraphy in patients with Parkinson’s disease

    J. Ebina, T. Sekiguchi, M. Takahashi, A. Inaba, S. Orimo (Tokyo, Japan)

    Objective: The aim of this study is to evaluate correlations among clinical features of Parkinson's disease (PD), odor stick identification test for Japanese (OSIT-J) score,…
  • « Previous Page
  • 1
  • …
  • 12
  • 13
  • 14
  • 15
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Life expectancy with and without Parkinson’s disease in the general population
    • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
    • An atypical and interesting feature of Parkinson´s disease
    • Effect of marijuana on Essential Tremor: A case report
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Patients with Essential Tremor Live Longer than their Relatives
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley